Cargando…
Erratum to “Development and validation of a clinical radiomics nomogram to predict secondary loss of response to infliximab in Crohn’s disease patients” [Heliyon 9(4) (April 2023) e14594]
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10360538/ https://www.ncbi.nlm.nih.gov/pubmed/37484401 http://dx.doi.org/10.1016/j.heliyon.2023.e16573 |
| _version_ | 1785076107092951040 |
|---|---|
| author | Zhu, Chao Wang, Xingwei Wang, Shihui Hu, Jing Gao, Yankun Li, Cuiping Li, Jianying Wu, Xingwang |
| author_facet | Zhu, Chao Wang, Xingwei Wang, Shihui Hu, Jing Gao, Yankun Li, Cuiping Li, Jianying Wu, Xingwang |
| author_sort | Zhu, Chao |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10360538 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Elsevier |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-103605382023-07-22 Erratum to “Development and validation of a clinical radiomics nomogram to predict secondary loss of response to infliximab in Crohn’s disease patients” [Heliyon 9(4) (April 2023) e14594] Zhu, Chao Wang, Xingwei Wang, Shihui Hu, Jing Gao, Yankun Li, Cuiping Li, Jianying Wu, Xingwang Heliyon Corrigendum Elsevier 2023-05-25 /pmc/articles/PMC10360538/ /pubmed/37484401 http://dx.doi.org/10.1016/j.heliyon.2023.e16573 Text en © 2023 Published by Elsevier Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
| spellingShingle | Corrigendum Zhu, Chao Wang, Xingwei Wang, Shihui Hu, Jing Gao, Yankun Li, Cuiping Li, Jianying Wu, Xingwang Erratum to “Development and validation of a clinical radiomics nomogram to predict secondary loss of response to infliximab in Crohn’s disease patients” [Heliyon 9(4) (April 2023) e14594] |
| title | Erratum to “Development and validation of a clinical radiomics nomogram to predict secondary loss of response to infliximab in Crohn’s disease patients” [Heliyon 9(4) (April 2023) e14594] |
| title_full | Erratum to “Development and validation of a clinical radiomics nomogram to predict secondary loss of response to infliximab in Crohn’s disease patients” [Heliyon 9(4) (April 2023) e14594] |
| title_fullStr | Erratum to “Development and validation of a clinical radiomics nomogram to predict secondary loss of response to infliximab in Crohn’s disease patients” [Heliyon 9(4) (April 2023) e14594] |
| title_full_unstemmed | Erratum to “Development and validation of a clinical radiomics nomogram to predict secondary loss of response to infliximab in Crohn’s disease patients” [Heliyon 9(4) (April 2023) e14594] |
| title_short | Erratum to “Development and validation of a clinical radiomics nomogram to predict secondary loss of response to infliximab in Crohn’s disease patients” [Heliyon 9(4) (April 2023) e14594] |
| title_sort | erratum to “development and validation of a clinical radiomics nomogram to predict secondary loss of response to infliximab in crohn’s disease patients” [heliyon 9(4) (april 2023) e14594] |
| topic | Corrigendum |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10360538/ https://www.ncbi.nlm.nih.gov/pubmed/37484401 http://dx.doi.org/10.1016/j.heliyon.2023.e16573 |
| work_keys_str_mv | AT zhuchao erratumtodevelopmentandvalidationofaclinicalradiomicsnomogramtopredictsecondarylossofresponsetoinfliximabincrohnsdiseasepatientsheliyon94april2023e14594 AT wangxingwei erratumtodevelopmentandvalidationofaclinicalradiomicsnomogramtopredictsecondarylossofresponsetoinfliximabincrohnsdiseasepatientsheliyon94april2023e14594 AT wangshihui erratumtodevelopmentandvalidationofaclinicalradiomicsnomogramtopredictsecondarylossofresponsetoinfliximabincrohnsdiseasepatientsheliyon94april2023e14594 AT hujing erratumtodevelopmentandvalidationofaclinicalradiomicsnomogramtopredictsecondarylossofresponsetoinfliximabincrohnsdiseasepatientsheliyon94april2023e14594 AT gaoyankun erratumtodevelopmentandvalidationofaclinicalradiomicsnomogramtopredictsecondarylossofresponsetoinfliximabincrohnsdiseasepatientsheliyon94april2023e14594 AT licuiping erratumtodevelopmentandvalidationofaclinicalradiomicsnomogramtopredictsecondarylossofresponsetoinfliximabincrohnsdiseasepatientsheliyon94april2023e14594 AT lijianying erratumtodevelopmentandvalidationofaclinicalradiomicsnomogramtopredictsecondarylossofresponsetoinfliximabincrohnsdiseasepatientsheliyon94april2023e14594 AT wuxingwang erratumtodevelopmentandvalidationofaclinicalradiomicsnomogramtopredictsecondarylossofresponsetoinfliximabincrohnsdiseasepatientsheliyon94april2023e14594 |